0001209191-19-043922.txt : 20190731
0001209191-19-043922.hdr.sgml : 20190731
20190731200406
ACCESSION NUMBER: 0001209191-19-043922
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190729
FILED AS OF DATE: 20190731
DATE AS OF CHANGE: 20190731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRYANT DOUGLAS C
CENTRAL INDEX KEY: 0001406652
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10961
FILM NUMBER: 19990506
MAIL ADDRESS:
STREET 1: C/O QUIDEL CORPORATION
STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUIDEL CORP /DE/
CENTRAL INDEX KEY: 0000353569
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 942573850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8585521100
MAIL ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/
DATE OF NAME CHANGE: 19910210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-07-29
0
0000353569
QUIDEL CORP /DE/
QDEL
0001406652
BRYANT DOUGLAS C
12544 HIGH BLUFF DRIVE, SUITE 200
SAN DIEGO
CA
92130
1
1
0
0
President & CEO
Common Stock
2019-07-29
4
M
0
21789
15.19
A
323231
D
Common Stock
2019-07-29
4
S
0
21789
57.78
D
301442
D
Non-Qualified Stock Options
15.19
2019-07-29
4
M
0
21789
0.00
D
2022-03-02
Common Stock
21789
75731
D
The weighted average sale price for these transactions was $57.78 per share, with a range of $57.125 to $58.98. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
60,196 shares vested on 03/02/2014; 30,098 shares vested on 03/02/2015; and 30,099 shares vested on 03/02/2016.
All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan.
Robert J. Bujarski, attorney-in-fact for Douglas C. Bryant
2019-07-31